Sharetreck – Tracking Genomic Investments & clinical trials for HIV.

Introduction:

In the dynamic landscape of gene therapies, recent developments have sparked significant attention among market watchers. The approval of Casgevy and Lovo-cel, coupled with Editas Medicine’s latest data release for Edit-301, has set the stage for a comprehensive analysis of the current state of affairs in the gene therapy arena.

Understanding Edit-301 and CD34+ Cells:

To comprehend Edit-301’s role in treating Sickle Cell Disease (SCD) and Transfusion-Dependent Thalassemia (TDT), we first need to delve into the science of CD34+ cells. CD34 is a crucial cell surface marker found on hematopoietic stem cells, which play a vital role in blood cell formation. These cells, both hematopoietic stem cells and progenitor cells, are central to therapeutic approaches due to their potential to differentiate into various blood cell types.

In the case of Edit-301 (Reni-cel), patient-derived CD34+ cells are edited to induce specific mutations related to fetal hemoglobin production. This personalized approach, utilizing the patient’s own cells, aims to enhance treatment efficacy by minimizing immune responses. The Ruby Trial for severe SCD and the Edithal trial for TDT mark significant strides in this groundbreaking therapy.

Vertex’s Move and the Legal Landscape:

Recent news of Vertex acquiring a non-exclusive license for CRISPR_Cas9 from Editas not only removes litigation risks but also bolsters Editas’ market position. This strategic move has contributed to a positive uptick in Editas’ shares and underscores the collaborative spirit within the gene therapy space.

Comparing Approvals and Financial Implications:

As Casgevy and Lovo-cel secure approvals, a closer look at their financial aspects is imperative. Casgevy, developed by Vertex and CRISPR Therapeutics, comes with a price tag of $2.1 million. In contrast, Bluebird Bio’s Lovo-cel is priced higher at $3.1 million, and it bears a black box warning from the FDA. Despite the warning, Bluebird has secured a significant partnership with a major insurer covering approximately a third of the American population.

Bluebird Bio’s Revenue Outlook:

Bluebird Bio’s Lovo-cel has garnered attention not only for its pricing but also for its strategic collaborations. With a performance-based pricing model covering three years of Value Over Expectation (VOE) or a partial refund, Bluebird has positioned itself favorably in the market. Analysts estimate a revenue of $170 million for Bluebird in 2024, factoring in all three of its gene therapies—Zynteglo, Skysona, and Lovo-cel. The recent share price rebound and a bullish price target of $7 indicate optimism among market analysts.

Future Considerations:

While these gene therapies offer groundbreaking solutions for challenging diseases, questions linger about their cost of production and the distribution of revenue as profit. The high upfront costs raise concerns, emphasizing the need to monitor these therapies’ performance and whether future technological innovations can contribute to cost reduction.

Conclusion:

The recent developments in the gene therapy landscape, marked by approvals, strategic collaborations, and breakthrough data releases, underscore the transformative potential of these therapies. As the market navigates uncharted territory, it becomes crucial to monitor the ongoing developments and assess the long-term impact on patients, stakeholders, and the broader healthcare ecosystem. We will find the outcome of performance based pricing and if it becomes an industry standard. At the end of 2024, we can expect to understand how Bluebird handles the performance based pricing in its balance sheet and how much of the liability of such pricing is realized in the first year. All these things can have an impact on the valuation of these companies.